Harvard Apparatus Regenerative Technology Inc. (OTCPK: HRGN)
Health Care · Biotechnology · US
$1.52
+8.50% today · -10.4% 1Y
Harvard Apparatus Regenerative Technology Inc. (OTCPK: HRGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $26.71M and employs 8 people.
Over the last twelve months the share price has lost 10.4%, trading between 0.96 and 2.22.
Tweenvest scores Harvard Apparatus Regenerative Technology Inc. across four factors: quality 13/100, value 52/100. Its strongest factor is value.
HRGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $26.71M
- Revenue (TTM)
- $982.00K
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- -0.35
- 52-week high
- $2.22
- 52-week low
- $0.96
- Avg volume (3M)
- —
- Shares outstanding
- 17.58M
- Employees
- 8
- Next earnings
- —
About Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
- ISIN
- US09074M2026
- Founded
- 2009
- Listed since
- Oct 21, 2013
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.